

Clinical trials of AZD0837

TrialResults-center www.trialresultscenter.org

1 atrial fibrillation

Trial	Treatments	Patients	Trials design and methods
AZD0837 vs aspirin			
phase 2 AZD0837 unpublished [NCT00623779] n=NA follow-up:	AZD0837 versus aspirin	patients with atrial fibrillation, who are appropriate for but unable or unwilling to take Vitamin-K antagonist(VKA) therapy	Parallel groups open
AZD0837 vs warfarin standard dose			
Lip (phase 2 AZD0837), 2009 unpublished [NCT00684307] n=636/318 follow-up: 3 or 9 months	AZD0837 for 3-9 months versus dose-adjusted Vitamin-K antagonists (VKA) (aiming for an international normalized ratio (INR) 2.0 to 3.0)	patients with non-valvular atrial fibrillation (AF) with one or more additional risk factors for stroke	Parallel groups double blind

More details and results :

- antithrombotics for atrial fibrillation in primary prevention of thromboembolic events at <http://www.trialresultscenter.org/go-Q57>
- direct oral anticoagulant (DAO) for atrial fibrillation in all type of patients at <http://www.trialresultscenter.org/go-Q391>

References

phase 2 AZD0837, 0:

unpublished

Lip (phase 2 AZD0837), 2009:

unpublished

Lip GY, Rasmussen LH, Olsson SB, Jensen EC, Persson AL, Eriksson U, Whlander KF Oral direct thrombin inhibitor AZD0837 for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation: a randomized dose-guiding, safety, and tolerability study of four doses of AZD0837 vs. vitamin K antagonists. Eur Heart J 2009;30:2897-907 [[19690349](#)] [10.1093/eurheartj/ehp318](https://doi.org/10.1093/eurheartj/ehp318)